Navigation Links
Idenix Pharmaceuticals Prices Public Offering of Common Stock
Date:4/8/2011

CAMBRIDGE, Mass., April 8, 2011 /PRNewswire/ -- Idenix Pharmaceuticals, Inc. (Nasdaq: IDIX), a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, today announced the pricing of an underwritten registered public offering of 18,310,000 shares of its common stock at a public offering price of $2.80 per share. All of the shares are being sold by Idenix. The offering is expected to close on April 13, 2011, subject to customary closing conditions.

J.P. Morgan Securities LLC is acting as sole book-running manager and underwriter for the offering. Idenix has granted the underwriter a 30-day option to purchase up to an additional 2,746,500 shares to cover over-allotments, if any.

The shares will be issued pursuant to a shelf registration statement on Form S-3 previously filed with and declared effective by the Securities and Exchange Commission. Idenix will also file with the Securities and Exchange Commission a prospectus supplement with respect to the offering.

This announcement shall not constitute an offer to sell or the solicitation of an offer to buy any securities of Idenix, nor shall there be any offer or sale of securities in any state or jurisdiction in which an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. Copies of the prospectus supplement and accompanying prospectus may be obtained, when available, from J.P. Morgan Securities LLC via Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717 or by calling toll-free (866) 803-9204.

About Idenix

Idenix Pharmaceuticals, Inc., headquartered in Cambridge, Massachusetts, is a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases. Idenix's current focus is on the treatment of infections caused by the hepatitis C virus.

Idenix Pharmaceuticals Contacts:
Kelly Barry (617) 995-9033 (media)
Eric Hoffman (617) 224-4485 (investors)


'/>"/>
SOURCE Idenix Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Idenix Pharmaceuticals Announces Proposed Public Offering of Common Stock
2. Idenix Announces Data Presentations at the 46th Annual Meeting of the European Association for the Study of the Liver (EASL)
3. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
4. Idenix Pharmaceuticals to Present at an Upcoming Investor Conference
5. Idenix to Host Conference Call Discussing Fourth Quarter and Year End 2010 Financial Results
6. Idenix Pharmaceuticals Reports Third Quarter and Nine Month 2010 Financial Results
7. Idenix Announces Data Presentations at the 61st Annual Meeting of the American Association for the Study of Liver Diseases (AASLD)
8. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
9. Idenix Pharmaceuticals Reports Fourth Quarter and Year End 2009 Financial Results
10. Idenix Pharmaceuticals Successfully Completes Proof-of-Concept Study of IDX184 for the Treatment of Hepatitis C Virus (HCV)
11. Idenix Pharmaceuticals and GlaxoSmithKline Sign Worldwide License Agreement for IDX899, a Novel NNRTI for the Treatment of HIV
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)...  Bodycad announced today that it has received ... for its Bodycad Unicompartmental Knee System, enabling the ... Bodycad is the first Canadian company to receive ... Bodycad,s revolutionary Unicompartmental Knee System ... patient,s unique anatomical features and kinematics. The system ...
(Date:3/29/2017)... 29, 2017 Research and Markets has announced ... report to their offering. ... The global energy-based aesthetic devices market to grow ... The report, Global Energy-Based Aesthetic Devices Market 2017-2021, has been ... experts. The report covers the market landscape and its growth prospects ...
(Date:3/29/2017)... 29, 2017 Global intravenous (IV) iron and oral ... 2021, growing at a CAGR of 5%. ... doctor to treat anemia or other iron deficiencies. Oral iron ... body. However, in some cases, oral administrations are not capable ... (IV) iron therapy comes into the picture. Global ...
Breaking Medicine Technology:
(Date:3/29/2017)... ... March 29, 2017 , ... During the last week of March, Chad ... to eligible individuals in the local community. , Colon cancer is the second ... detect colon cancer while it is small, confined and easier to treat. If you ...
(Date:3/29/2017)... ... March 30, 2017 , ... Grass pollen is the main cause of hay fever in ... The season for grass pollen runs from May to July each year; with the worst ... to do? HayMax™ allergen barrier balms ( http://www.haymax.us ) provide an effective defense against grass ...
(Date:3/29/2017)... ... 29, 2017 , ... Wells Pharmacy Network, a proud A4M ... upcoming World Congress, in Hollywood Florida April 6-8, 2017. , Ben David, CEO ... leader in the training of physicians, scientists, and members of the public on ...
(Date:3/29/2017)... WI (PRWEB) , ... March 29, 2017 , ... Dr. ... on early orthodontic treatment and accepting new pediatric patients, with or without a referral. ... young patients have a better orthodontic outcome and experience. When patients receive early treatment, ...
(Date:3/29/2017)... ... March 29, 2017 , ... An inventor from ... rubber bands used in conjunction with my braces always rubbed against the inside ... way to prevent this problem." The O.B.S. was the result of his brainstorming. ...
Breaking Medicine News(10 mins):